These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30942459)

  • 41. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
    Kikuchi J; Koyama D; Wada T; Izumi T; Hofgaard PO; Bogen B; Furukawa Y
    J Clin Invest; 2015 Oct; 125(12):4375-90. PubMed ID: 26517694
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
    Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
    Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
    Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhancer of zeste homolog 2 (EZH2) inhibitors.
    Gulati N; Béguelin W; Giulino-Roth L
    Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EZH2 inhibitors: a patent review (2014-2016).
    Stazi G; Zwergel C; Mai A; Valente S
    Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
    Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
    Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.
    Otsuka Y; Nishikori M; Arima H; Izumi K; Kitawaki T; Hishizawa M; Takaori-Kondo A
    Mol Immunol; 2020 Mar; 119():35-45. PubMed ID: 31962268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
    Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
    Hayden A; Johnson PW; Packham G; Crabb SJ
    Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
    O'Brien E; Tse C; Tracy I; Reddin I; Selfe J; Gibson J; Tapper W; Pengelly RJ; Gao J; Aladowicz E; Petts G; Thway K; Popov S; Kelsey A; Underwood TJ; Shipley J; Walters ZS
    Clin Epigenetics; 2023 Oct; 15(1):167. PubMed ID: 37858275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors.
    He H; Hu X; Teng F; Liu Z; Zhang Q; Feng Z; Feng Q; Yu L
    Bioorg Med Chem Lett; 2020 Mar; 30(5):126957. PubMed ID: 31959420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
    Ning X; Shi Z; Liu X; Zhang A; Han L; Jiang K; Kang C; Zhang Q
    Cancer Lett; 2015 Apr; 359(2):198-205. PubMed ID: 25595591
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting of cancer stem cells by inhibitors of DNA and histone methylation.
    Momparler RL; Côté S
    Expert Opin Investig Drugs; 2015; 24(8):1031-43. PubMed ID: 26004134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
    Christofides A; Karantanos T; Bardhan K; Boussiotis VA
    Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.
    Lv YF; Yan GN; Meng G; Zhang X; Guo QN
    Sci Rep; 2015 Aug; 5():12999. PubMed ID: 26265454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.
    Ougolkov AV; Bilim VN; Billadeau DD
    Clin Cancer Res; 2008 Nov; 14(21):6790-6. PubMed ID: 18980972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A.
    Licht JD
    Trans Am Clin Climatol Assoc; 2018; 129():24-36. PubMed ID: 30166694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.